Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the following 7 stocks made the list for top value stocks in the Biotechnology & Medical Research industry. Those looking for value stocks to add to their portfolio may want to use this list as a starting point for further investment research.

Latest Biotechnology & Medical Research Stock News

Before choosing which top Biotechnology & Medical Research stock to buy, be sure to conduct proper due diligence: analyze various financial metrics and look at historical data, public statements and news coverage.

The Biotechnology and Medical Research sub-industry has a positive outlook, a historically defensive sub-industry. Drug sales are anticipated to have high growth, primarily driven by COVID-19 therapeutics, the continued adoption of many new and innovative therapies, a favorable M&A environment, and a low prevalence of patent expirations in 2022. Additionally, companies could see prescription growth pick up as in-person physician visits return to pre-pandemic levels. As COVID-19 variants have emerged, vaccine boosters have been offered in order to increase efficacy. Due to this, repeat vaccinations will likely be necessary for lifelong immunity which would provide a long-lasting and significant source of revenue for lead vaccine developers. Aside from vaccines, the biotech industry is dependent on the volume of new therapy approvals. The FDA’s heavy focus on COVID-19 could slow the approvals on non-COVID-19 therapies. Despite this, the biotech industry will likely see promising sales growth over the next five years as it usually takes at least five years for new drugs to reach peak sales levels. Approval activity has also been on the rise recently. Mergers and acquisitions activity is expected to remain low as a more activist Federal Trade Commission (led by Lina Khan) could be more skeptical of proposed mergers. Year to date through June 30, the S&P 1500 Biotech Index was down 1.6%, vs. a 20.5% decline for the S&P 1500 Composite Index. In 2021, the Biotech Index rose 8.2%, vs. a 26.7% gain for the Composite Index.

Why Focus on Undervalued Biotechnology & Medical Research Stocks?

Value investors seek to buy stocks at a discount to their intrinsic value. Long-term returns show that such strategies are advantageous. Value stocks, as a group, tend to outperform growth stocks over extended periods of time. Typically, value investors perform financial analysis of numerous metrics, don’t follow the herd and are long-term investors.

AAII’s A+ Investor Value Grade is derived from a stock’s Value Score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

What Goes Into AAII’s Value Grade?

Stock evaluation requires access to huge amounts of data as well as the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movement. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors with that task.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for more than just value. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others. Some stocks may even have null values for certain metrics like the price-earnings ratio or the price-to-book ratio but not others. An example of this would be a company with losses instead of profits or a negative book value because of heavy borrowing. Negative earnings or book value result in non-meaningful ratios that are left blank or null.

Click the button below to learn more about A+ Investor and subscribe today.

7 Undervalued Biotechnology & Medical Research Stocks

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 7 undervalued stocks in the Biotechnology & Medical Research industry for Tuesday, March 21, 2023. Let’s take a closer look at their individual scores to see how they measure up against each other and the Biotechnology & Medical Research industry median.

The Value Grade is assigned based on how each stock’s composite valuation compares to all other stocks.

The process for assigning grades starts with each variable for a given stock. The percentile rankings for all valid ratios that a stock has are calculated. So, for instance, a stock could have a price-to-book ranking in the 43rd percentile, a price-earnings ranking in the 67th percentile, a price-to-sales ranking in the 23rd percentile, etc. Then, those rankings are averaged for each stock. (A minimum of two valid variables are required, though all six will be used if available.)

Once the average of the individual variables is calculated, that average is ranked against all stocks. Put another way, each stock’s composite valuation is compared to all other stocks. These ranks are then sorted into quintiles from the cheapest 20% (a grade of A) to the most expensive 20% (a grade of F).

As always, we recommend that you conduct proper due diligence and research before investing in any security. We also suggest that investors utilize numerous grades, not just value, when it comes to deciding whether a company is a good fit for their allocation needs.

Codiak BioSciences Inc’s Value Grade

Value Grade:

Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of exosome-based therapeutics. The Company has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. It utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The Company's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The Company's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Codiak BioSciences Inc has a Value Score of 89, which is considered to be undervalued.

When you look at Codiak BioSciences Inc’s price-to-sales ratio at 0.36 compared to the industry median at 8.61, this company has a lower price relative to revenue compared to its peers. This could make Codiak BioSciences Inc’s stock more attractive for value investors.

Now, let’s assess Codiak BioSciences Inc’s EV/EBITDA ratio, also known as enterprise multiple. At 0.1, when compared to the industry median of 0.9, the company may be considered undervalued in relation to its peers. Value investors could use the enterprise multiple to identify stocks that are considered overvalued or undervalued relative to their industry.

Shareholder yield is the sum of a stock’s dividend yield (paid over previous 12 months minus special dividends) and the percentage of net share buybacks over the previous 12 months. Codiak BioSciences Inc’s shareholder yield is lower than its industry median ratio of (5.53%). Value investors may look for an attractive shareholder yield because it can be a powerful tool for identifying if the company has a good management team.

As one of the most common value metrics, the price-to-book ratio evaluates a company’s current market price relative to its book value. Codiak BioSciences Inc’s price-to-book ratio is lower than its industry median ratio of 1.43. This could make Codiak BioSciences Inc more attractive to investors looking for a new addition to their portfolio.

Enveric Biosciences Inc’s Value Grade

Value Grade:

Enveric Biosciences, Inc. is an early-development-stage biosciences company. The Company is developing next-generation mental health and oncology treatments using a clinical discovery platform to enable psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. It is developing its product candidates that are focused on cannabinoids derived from non-hemp botanical sources, and synthetic materials containing no tetrahydrocannabinol (THC) in order to comply with United States federal regulations. Its product candidates include EV104, EVM-101, EVM-201, EVM-301, EV102 and EV101. EV104 includes cannabidiol (CBD) and celecoxib conjugate. EVM-101 is a first-generation psychedelic asset, which is a psilocybin oral formulation. EVM-201 is a second-generation psychedelic asset, which is a prodrug of psilocin. EVM-301 is a third-generation psychedelic. EV102 is a cannabinoid cream for topical skin application. EV101 is a cannabinoid plus chemotherapy combination therapy.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Enveric Biosciences Inc has a Value Score of 76, which is considered to be undervalued.

Enveric Biosciences Inc’s price-to-book ratio is higher than its peers. This could make Enveric Biosciences Inc less attractive for value investors when compared to the industry median at 1.43.

You can read more about Enveric Biosciences Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

IO Biotech Inc’s Value Grade

Value Grade:

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

IO Biotech Inc has a Value Score of 100, which is considered to be undervalued.

IO Biotech Inc’s price-to-book ratio is higher than its peers. This could make IO Biotech Inc less attractive for value investors when compared to the industry median at 1.43.

You can read more about IO Biotech Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Jounce Therapeutics Inc’s Value Grade

Value Grade:

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. The Company has developed a suite of integrated technologies that consist of its Translational Science Platform, enabling it to interrogate the cellular and molecular composition of tumors. Its program, JTX-8064, is a humanized IgG4, anti-LILRB2 monoclonal antibody designed to reprogram macrophages. JTX-8064 is being developed for patients with either PD-(L)1-inhibitor resistant or PD-(L)1 inhibitor-sensitive tumors. Vopratelimab is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS). Pimivalimab is a clinical-stage anti-PD-1 monoclonal antibody that is being developed primarily for its use in combination with its product candidates.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Jounce Therapeutics Inc has a Value Score of 87, which is considered to be undervalued.

Jounce Therapeutics Inc’s price-to-book ratio is higher than its peers. This could make Jounce Therapeutics Inc less attractive for value investors when compared to the industry median at 1.43.

You can read more about Jounce Therapeutics Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Liminal BioSciences Inc’s Value Grade

Value Grade:

Liminal BioSciences Inc. is a Canada-based development-stage biopharmaceutical company. The Company is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The Company is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Liminal BioSciences Inc has a Value Score of 63, which is considered to be undervalued.

Liminal BioSciences Inc’s price-to-book ratio is higher than its peers. This could make Liminal BioSciences Inc less attractive for value investors when compared to the industry median at 1.43.

You can read more about Liminal BioSciences Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Lumos Pharma Inc’s Value Grade

Value Grade:

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Lumos Pharma Inc has a Value Score of 66, which is considered to be undervalued.

Lumos Pharma Inc’s price-to-book ratio is higher than its peers. This could make Lumos Pharma Inc less attractive for value investors when compared to the industry median at 1.43.

You can read more about Lumos Pharma Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Mustang Bio Inc’s Value Grade

Value Grade:

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that is focused on translating medical breakthroughs in cell and gene therapies into cures for hematologic cancers, solid tumors and rare genetic diseases. The Company's pipeline is focused on three core areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. Its products include MB-107 and MB-207 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency (XSCID). XSCID is a rare genetic immune system condition also known as bubble boy disease. It is developing CAR T therapies for hematologic malignancies in partnership with COH targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutch targeting CD20 (MB-106). The Company is also developing CAR T therapies for solid tumors in partnership with COH targeting IL13Ra2 (MB-101), HER2 (MB-103) and PSCA (MB-105).

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Mustang Bio Inc has a Value Score of 79, which is considered to be undervalued.

Mustang Bio Inc’s price-to-book ratio is higher than its peers. This could make Mustang Bio Inc less attractive for value investors when compared to the industry median at 1.43.

You can read more about Mustang Bio Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Other Biotechnology & Medical Research Stock Grades

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate revisions and quality—on the A+ Stock Grades Screener.

Also, if you want full access to all of AAII’s premium services, you can subscribe to one convenient bundled plan called AAII Platinum where you can try out A+ Investor, AAII Dividend Investing, the Stock Superstars Report, Growth Investing and VMQ Stocks. With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about Biotechnology & Medical Research stocks as well as other industrys.

Choosing Which of the 7 Best Biotechnology & Medical Research Stocks Is Right for You

Choosing which value stocks to invest in will ultimately depend on your individual goals and allocation; however, comparing similar value stocks in the same industry can help you analyze which might be better investments for you in the long run. So, let’s take a look at the Value Grade for all of our stocks.

• Codiak BioSciences Inc stock has a Value Grade of A.
• Enveric Biosciences Inc stock has a Value Grade of B.
• IO Biotech Inc stock has a Value Grade of A.
• Jounce Therapeutics Inc stock has a Value Grade of A.
• Liminal BioSciences Inc stock has a Value Grade of B.
• Lumos Pharma Inc stock has a Value Grade of B.
• Mustang Bio Inc stock has a Value Grade of B.

Now that you have a bit more background about each of the 7 undervalued stocks in the Biotechnology & Medical Research industry as well as their overall grades, it’s time for you to conduct additional research to see if these could fit your portfolio needs based on your goals and risk tolerance. AAII can help you figure out both and identify which investments align with what works best for you.

We do so through a program of education that teaches you to invest for yourself and become an effective manager of your own wealth—no more relying on others for your financial independence. You can rely on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis that makes you a better investor.

A+ Investor adds to that qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

Additional Resources About Biotechnology & Medical Research Stocks

Want to learn more about Biotechnology & Medical Research stocks to see if they could be the right investment for you? Check out some additional resources and articles to help you on your financial journey.

• 7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, March 21
• 3 Undervalued Biotechnology & Medical Research Stocks for Monday, March 20
• Why Arcutis Biotherapeutics Inc’s (ARQT) Stock Is Up 4.33%
• Why Exelixis Inc’s (EXEL) Stock Is Up 4.44%

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith and we accept no liability for any errors or omissions. The full disclaimer can be read here.